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22 ABSTRACT
23 Wound healing is a complex and costly public health problem that should be timely 
24 addressed to achieve a rapid and adequate tissue repair avoiding or even eliminating 
25 potential pathogenic infection. Chronic infected non-healing wounds represent a serious 
26 concern for health care systems. Efficient wound dressings with tailored therapy having the 
27 best response and highest safety margin for the management of chronic non-healing 
28 wounds are still needed. The use of novel wound dressing materials has emerged as a 
29 promising tool to fulfil these requirements. In this work, asymmetric electrospun 
30 polycaprolactone (PCL)-based nanofibers (NFs) were decorated with electrosprayed 
31 poly(lactic-co-glycolic acid) microparticles (PLGA MPs) containing the natural 
32 antibacterial compound thymol  (THY) in order to obtain drug eluting antimicrobial 
33 dressings having sustained release. The synthesized dressings successfully inhibited the in 
34 vitro growth of Staphylococcus aureus ATCC 25923, showing also at the same doses 
35 cytocompatibility on human dermal fibroblasts and keratinocyte cultures after treatment for 
36 24h, which was not observed when using free thymol. An in vivo murine excisional wound 
37 splinting model, followed by the experimental infection of the wounds with S. aureus and 
38 their treatment with the synthesized dressings, pointed to the reduction of the bacterial load 
39 in wounds after 7 days, though the total elimination of the infection was not reached. The 
40 findings indicated the relevance of the direct contact between the dressings and the bacteria, 
41 highlighting the need to tune their design considering the wound surface and the nature of 
42 the antimicrobial cargo contained.
43 Keywords: wound infection, dressing, electrospinning, antibacterial nanomaterials, thymol, 
44 in vivo murine model, non-healing wounds.
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45 1. Introduction
46 Acute wounds including surgical wounds, burns, pressure and diabetic foot ulcers, fistulas, 
47 edemas, etc. may suffer from potential bacterial infection and subsequent impaired healing 
48 and even possible chronification. Bacterial colonization can be originated by the host 
49 microbiota present on the skin or in other parts of the body or by environmental exposure to 
50 pathogenic microorganisms. Infected wounds are treated by debridement (i.e., removal of 
51 devitalized tissue), cleansing, drainage and, depending on the wound culture results, 
52 systemic or topical antibiotic treatment. Different reports have quantified the direct and 
53 indirect costs associated to chronic non-healing infected wounds and all of them alert about 
54 population aging and comorbid growing illnesses, such as diabetes, as concerns which 
55 might increase even further the tremendous social and health care burden that they 
56 represent [1,2].
57 After wounding, dressings are primary used to protect the new forming tissue from external 
58 physical and biological contamination, to control the drainage of excess fluid and potential 
59 bleeding and to allow adequate vapor permeability to avoid maceration. Drug-eluting 
60 wound dressings are used to locally release a drug, antibiotic or antiseptic to remove 
61 pathogenic bacteria and accelerate the natural healing process while preventing the bacteria 
62 from leaking out and spreading. Some of the commercially available ones include silver 
63 and gentamicin in their formulation to take advantage of the wide antimicrobial spectrum of 
64 the former and the antibiotic activity of the later against a wide range of bacterial strains, 
65 mostly Gram-negative bacteria [3]. One of the limitations to overcome of topic antibiotics 
66 and antiseptics is the potential cytotoxicity against eukaryotic cells of the released 
67 antimicrobial, as well as the potential development of bacterial antibiotic resistance. Also, a 
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68 prolonged antimicrobial release from the dressing is sought considering that during the 
69 healing process potential bacterial contamination might occur at any time. Molecular 
70 genetics have determined the existence of silver resistance thanks to the identification of 
71 the responsible bacterial plasmids and genes [4]. Likewise, gentamicin resistance was 
72 initially reported early in 1970 soon after its discovery (1963) [5]. In addition, topical 
73 antibiotics avoid systemic side effects, provide with a localized targeted effect on the 
74 wound bed and allow the use of some antibiotics that are disapproved for systemic 
75 administration. However, cytotoxicity on human cells due to the high site concentration 
76 remains as the main limitation of topical antibiotics as well as the aforementioned potential 
77 development of antibiotic resistance. Gentamicin, for instance, presents as adverse side 
78 effects ototoxicity and nephrotoxicity as well as keratinocyte inhibition when used topically 
79 at high doses [6]. Gentamicin loaded electrospun wound dressings have previously shown 
80 at short times higher cytotoxicity against human fibroblasts than controls and a delayed 
81 healing process [7]. Silver is cytotoxic against keratinocytes and fibroblasts and may inhibit 
82 re-epithelialization when extensively applied on the infected wound bed [8]. Therefore, 
83 antimicrobial resistance and toxicity against eukaryotic cells remain as drawbacks needed 
84 to be addressed. Several other wound dressings have been developed to reduce the 
85 antibiotic cytotoxicity on human cells by fine-tuning its release kinetics while having large 
86 antibacterial action [9–12]; however, in those pads, antibiotic resistance remains still as a 
87 foremost threat. In addition, there is limited evidence for differences between wound 
88 dressings for any outcome in some non-healing chronic wounds such as foot ulcers in 
89 people with diabetes [13]. Therefore, efficient wound dressings with tailored therapy 
90 having the best response and highest safety margin for the management of chronic non-
91 healing wounds are still needed.
5
92 After analyzing 1770 wounds, Twum-Danso et al. identified Staphylococcus aureus 23.7%, 
93 Escherichia coli 16.9%, Staphylococcus epidermidis 13.5% and Pseudomonas aeruginosa 
94 13.0% as the most common pathogens identified in intra-operative wounds whereas 
95 Enterobacter spp., Proteus spp., Klebsiella spp. and P. aeruginosa had a higher presence 
96 on postoperative wounds [14]. The microbiological analysis of chronic infected wounds 
97 such as diabetic foot ulcers from 313 tissue samples obtained from 222 patients previously 
98 treated with antibiotics identified Pseudomonas aeruginosa and Acinetobacter spp. as the 
99 most common pathogens in both bone and soft tissues [15]. However, the identification of 
100 specific bacteria in a wound does not necessary mean that the wound is infected. 
101 Genotyping by DNA sequencing aids in identifying the complete combined microbiome in 
102 infected wounds. However, the identification of planktonic bacteria is not an easy task 
103 because its growth is a dynamic process that changes over time, depends on the sampling 
104 methods used and the bacteria is not homogeneously distributed along the wound and also 
105 it is not only present on the external surface but also it can be present deeply in the tissue. 
106 Another additional limitation is that molecular assays such as 16S rRNA PCR and the ones 
107 based on partial ribosomal amplification are able to identify bacteria including viable but 
108 nonculturable (VBNC) bacteria but genetic material coming from non-viable bacteria is 
109 also accounted when using those analytical techniques [16].
110 The complexity of identifying the microbiome present in infected wounds is a handicap and 
111 also the already mentioned antibiotic resistance but, in addition, the presence of bacterial 
112 biofilm associated to non-healing chronic (> 1 month) infected wounds represents a major 
113 limitation that constitutes a serious concern. The identification of bacterial biofilm on 
114 infected wounds is not a straightforward task and a compendium between morphological 
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115 and microscopic analysis, conventional microbiological techniques and molecular assays 
116 including transcriptomics and wound blotting are recommended to confirm its presence 
117 [16]. In 2017, a Global Wound Biofilm Expert Panel delivered a consensus document 
118 settling the guidelines for the identification and treatment of biofilms in chronic non-
119 healing wounds [17]. Two key guidelines with which all the experts strongly agree were 
120 that: 1) Repeated debridement alone fails in preventing biofilm regrowth and the use of 
121 topical antiseptics up to 24h after debridement reduces the chances of forming biofilm 
122 within this time-dependent window and 2) A sustained active level of antimicrobial at a 
123 concentration above the Minimum Biofilm Eradication Concentration (MBEC) is required 
124 to prevent biofilm formation. Therefore, a sustained antimicrobial release should be 
125 provided within this time-dependent window after debridement and novel drug-eluting 
126 dressings with sustained antimicrobial release are demanded.
127 Herein, we have developed drug eluting antimicrobial dressings with time-controlled drug 
128 release and with the ability to release natural-origin antiseptics. Asymmetric electrospun 
129 dressings were obtained by decorating polycaprolactone (PCL) nanofibers (NFs) with 
130 electrosprayed poly(lactic-co-glycolic acid) microparticles (PLGA MPs) containing the 
131 natural antimicrobial cargo. As we mentioned before, a prolonged antimicrobial release 
132 from the dressing is sought considering that during the healing process potential bacterial 
133 contamination might occur at any time. Those natural compounds have multiple 
134 mechanisms of antimicrobial action and the chances for the bacteria of acquiring 
135 simultaneous genetic mutations are reduced compared to the use of antibiotics, which 
136 usually have a single target. THY was the natural monoterpenoid phenol chosen due to its 
137 well-known antimicrobial [18–20] and anti-inflammatory [21] action. It is well known that 
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138 proinflammatory cytokines are overexpressed in chronic wounds [16] therefore; healing can 
139 be promoted by the sustained release of compounds with both antiseptic and anti-
140 inflammatory effects. In this work, at the same doses, non cytotoxicological effects were 
141 observed on eukaryotic cells whereas antimicrobial action was observed, and a sustained 
142 release was responsible of an increased antimicrobial action over time. We previously 
143 fabricated electrospun PCL-based THY-loaded nanofibers [22] and tested their 
144 antimicrobial efficacy in vitro. However, in that preliminary study only the THY present on 
145 the external surface of the nanofibers was released (~7% of the thymol loaded) and the rest 
146 of the thymol incorporated (~93%) remained in the interior of the fibers due to the slow 
147 degradative rate of PCL. Herein, we have included THY within PLGA-based 
148 microparticles decorating the nanofibers in order to achieve a sustained release of the 
149 antimicrobial compound for a long time. We took advantage of the hydrolytic character of 
150 the ester bonds present in PLGA to release large amounts of the encapsulated antibacterial 
151 compound in a sustained manner providing with a pharmacokinetic control of the release.
152 2. Materials and methods 
153 2.1. Materials
154 PCL (Mn = 80000 Da), (S)-(-)-limonene (food grade ≥ 95 %), naproxen sodium salt (98-
155 102 %), piperonal (3,4-(methylenedioxy)benzaldehyde, 99.8%), phosphate buffer saline 
156 (PBS) and Tween 80 were purchased from Sigma-Aldrich. Dichloromethane (DCM > 99 
157 %) and N,N-dimethylformamide (DMF > 99 %) were obtained from Fisher Scientific. 
158 PLGA RESOMER RG 504 was purchased from Evonik Industries AG. Thymol (99 %) was 
159 purchased from Acros Organics. Trypticase in soy broth (TSB) and trypticase in soy agar 
160 (TSA) were obtained from Laboratorios Conda-Pronadisa S.A. Deuterated chloroform 
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161 (99.8 % D), acetonitrile (≥ 99.9 %), methanol (≥ 99.9 %) and formic acid (98-100 %) were 
162 purchased from VWR. Dulbecco’s Modified Eagle’s Medium (DMEM) containing L-
163 glutamine (2 mM) and antibiotics (1 % penicillin-streptomycin-amphotericin B) was 
164 obtained from Biowest. Fetal Bovine Serum (FBS, 10 % v/v) was used for supplement 
165 DMEM and purchased from Gibco. All reagents were used without any further purification.
166 2.2. Fabrication of PCL electrospun mats decorated with electrosprayed thymol-
167 loaded PLGA microparticles
168 Initially, nanofibrous mats were prepared by electrospinning in an Yflow 2.2 D500 
169 electrospinner equipped with an 8 cm aluminium disc covered with an aluminium foil as 
170 collector. A solution of PCL (10 % w/w) was prepared by overnight stirring it at room 
171 temperature in a mixture of DCM and DMF (1:1 v/v). A 10 mL syringe was filled with the 
172 polymeric solution that was sonicated for 15 min to remove occluded air bubbles before 
173 connecting it with the electrospinner.
174 A 2D module (to allow the dual axis movement of the needle) was used in order to obtain 
175 mats with homogenous thicknesses. A 22-gauge needle was used and the distance needle-
176 collector was fixed at 18 cm with a flow rate fixed at 1.0 mL/h. The voltage applied to the 
177 collector was -4.00 kV and the voltage applied to needle was +10.50 kV. All samples were 
178 obtained at room temperature with a relative humidity between 30 and 50 %. 
179 After synthesis, empty or THY-loaded MPs were electrosprayed on one side of the 
180 electrospun mat surface in order to obtain mats decorated with electrosprayed THY-loaded 
181 PLGA MPs or free of THY as controls. With this purpose, a solution of PLGA (10 % w/w) 
182 in DMF containing different amounts of THY (0, 2.5, 5, 7.5, 10 and 15 wt. % referred to 
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183 the PLGA mass) was loaded in 10 mL syringes that were subsequently degassed by 
184 sonication for 15 min to remove potentially occluded air bubbles. Different amounts of 
185 THY were loaded within the electrosprayed PLGA microparticles in order to control the 
186 total amount of THY incorporated in the dressings. In our previous studies we evaluated the 
187 minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) 
188 for free THY against planktonic bacteria [19] and when incorporated within electrospun 
189 PCL nanofibers [22] highlighting the importance of the direct contact between bacteria and 
190 the antimicrobial mat to elicit antibacterial effects.
191 The same Yflow 2.2 D500 electrospinner and collector were employed to spray the thymol-
192 loaded microparticles on the separately prepared mats. A 22-gauge needle was located at 30 
193 cm from the collector plate where the previously prepared mat was placed. Flow rate was 
194 set at 0.5 or 1.0 mL/h. The voltage applied to collector was -4.30 kV and the voltage 
195 applied to the needle varied from +10.08 to +14.10 kV in order to obtain a stable Taylor 
196 cone jet. All samples were obtained at room temperature and a relative humidity between 
197 30 % and 50 %. Hence, the MPs with THY (or without it as controls) were electrosprayed 
198 on one side of the previously prepared PCL electrospun mats.
199 2.3. Characterization of the hybrid mats
200 Scanning electron microscopy (SEM) was used for the morphological characterization of 
201 the materials prepared. Each sample was covered with a 5 nm Pd layer before the 
202 visualization in an Inspect F-50 SEM microscope. PLGA MPs and NFs diameters and 
203 standard deviations were measured using the ImageJ software (N = 100).
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204 For the mechanical characterization of the fabricated mats, six samples per mat were cut 
205 into 50 mm × 10 mm pieces and subjected to a tensile test. Mechanical properties were 
206 determined using a uniaxial Instron test machine (Instron, US) with video extensometer 
207 5548 (1 KN load cell, 1 mm/min). 
208 Thymol concentration in the microparticles was determined by GC-MS. A calibration curve 
209 for THY was prepared from 1 to 50 ppm with 5 ppm of S-(-)-limonene as internal standard. 
210 Un-supported thymol-loaded microparticles (10 mg) were dissolved in 10 mL of 
211 acetonitrile. 500 µL of solution (with an adequate concentration of internal standard) was 
212 mixed with 500 µL of methanol, centrifuged for 15 min at 13300 rpm and supernatant was 
213 filtered (200 nm cut off) in order to remove precipitated PLGA. Supernatant was diluted 
214 with methanol (to fit the sample concentration to the calibration curve) and analysed in a 
215 Shimadzu 2010SE GC-MS chromatograph with an AOC 20i injector. A Zebron ZB-50 
216 capillary column (30 m x 0.25 mm, 0.25 µm thickness, Phenomenex) was used. The 
217 chromatographic method included a heating increase from room temperature to 50 °C with 
218 a dwell time of 1 min then an increase at 160 °C at 10 °C/min and a final rise to 200 °C at 
219 20 °C/min. Helium, at a constant flow rate of 1.0 mL/min, was used as carrier gas. The 
220 detector temperature was 250 °C and the transfer line and ion source temperature were both 
221 set at 200 °C. For analysis, 1 µL of sample was injected, working with a split ratio of 1:10. 
222 Data were obtained from three independent experiments run in duplicate.
223 Also, a quantitative 1H NMR (qNMR) method has been used to confirm the percentage of 
224 PLGA ester and THY loaded in the hybrid mats.1H NMR spectra were recorded at 400 
225 MHz on a NMR spectrometer (Bruker DPX 400, Bruker Daltonik GmbH) over a spectral 
226 width of 0-13 parts per million (ppm) and chemicals shift values (δ) were reported in ppm. 
11
227 To obtain the maximum signal intensity of each proton in quantitative NMR spectra, an 
228 optimization of relaxation delay parameter, D1, has been performed. For that, the inversion 
229 recovery-pulse sequence was used to calculate spin-lattice relaxation, T1, in PCL, PLGA 
230 ester, THY and internal standard (piperonal) solutions, while the 90° pulse width was 
231 10.4μs. The highest value at T1 was 4.45 s, corresponding to the piperonal signal with 
232 chemical shift at 9.80 ppm. Therefore, the D1 parameter was fixed at 15 s (more than 3 
233 times the T1 value). Other values for the acquisition parameters of the 1H NMR spectra 
234 were as follows: acquisition time (1s); number of scans (16); temperature (27.0 °C).
235 For sample measure, piperonal was used as internal standard and five calibration solutions 
236 were prepared. Solutions were prepared in 5 mm OD NMR tube from four standard 
237 solutions in CDCl3 of PCL (4 mg/mL), PLGA (4 mg/mL), thymol (4 mg/mL) and piperonal 
238 (5 mg/mL). The amount of piperonal was the same for samples and calibration curves. The 
239 signal selected from 1H NMR spectra to assign the integral value of 1 was the singlet signal 
240 of piperonal at 9.80 ppm. For quantification of thymol, PLGA ester and PCL, the doublet 
241 signal at 7.05 ppm of THY, the multiplet signal at 4.53-4.95 ppm of PLGA ester and the 
242 multiplet signal at 3.95-4.10 ppm of PCL were chosen. Lineal regression plots were 
243 obtained in order to calculate the mass of PLGA ester per mass of internal standard and the 
244 mass of THY per mass of internal standard. Data were obtained from three independent 
245 experiments run in duplicate.
246 2.4. In vitro release kinetics of PCL-electrospun mats decorated with thymol-
247 loaded microparticles
248 25 mg of the PCL-electrospun mats decorated with THY-loaded microparticles were 
249 immersed in 10 mL of PBS (with Tween 80, 2 % w/v). Samples were kept at 37 °C with a 
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250 constant agitation (250 rpm). PBS was replaced at different time (each 0.5 h from 0 to 3h, 
251 each hour from 3 to 8 h, 24, 72, 120, 192 and 360h). Collected samples were analysed by 
252 UPLC with an Acquity UPLC® Waters liquid chromatographic system equipped with a 
253 column heater, a photodiode array detector ACQ-PDA, a quaternary solvent manager 
254 ACQ-QSM and a sample manager ACQ-FTN controlled by Waters® EmpowerTM 
255 chromatographic software. An Acquity UPLC® Waters BEH C18 column (2.1 x 50 mm, 
256 1.7 µm particle diameter) protected by 0.2 µm stainless steel In-Line Filter with a Holder 
257 Waters was used.
258 A calibration curve from 2.5 to 300 ppm was prepared for the THY analysis. 25 ppm of 
259 naproxen sodium salt was added to the samples as internal standard. For the analysis, an 
260 isocratic method at 40 °C was employed. Mobile phase was composed by a mixture of 
261 acetonitrile and milli-Q water (with formic acid, 0.1 % v/v) in a proportion 50:50 in 
262 volume. THY was detected and quantified using the PDA detector set at 275 nm 
263 wavelength. THY released concentrations were obtained from three independent 
264 experiments run in duplicate and analysed in triplicate by UPLC. 
265 To evaluate the release kinetics, data fitted the Peppas-Sahlin model. The correlation 
266 coefficient (R2) value was calculated from the linear regression of these plots by means of 
267 the following equation (Eq. 1):
268 Peppas-Sahlin model:             [Eq. 1]
𝑀𝑡
𝑀𝑇 = 𝑘1𝑡
𝑛 + 𝑘2𝑡2𝑛
269 where Mt/MT is the drug release fraction at time t; k1 and k2 are constants from Fickian 
270 diffusional contribution and case-II relaxation contribution, respectively; n is the 
271 diffusional exponent that can be related to the drug transport mechanism. 
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272 2.5. Antibacterial activity determination
273 Antibacterial activity of synthetized materials against Staphylococcus aureus ATCC 25923 
274 (Ielab) was tested with the Antimicrobial Disk Susceptibility Tests of the US Clinical and 
275 Laboratory Standards Institute (CLSI) [23]. The PCL electrospun mats developed (PCL 
276 electrospun NFs, PCL electrospun NFs decorated with PLGA microparticles (PCL 
277 NFs@PLGA MPs), and PCL electrospun NFs decorated with electrosprayed thymol-loaded 
278 PLGA microparticles (PCL NFs@PLGA-THY MPs) were cut as discs of different 
279 diameters (12, 14, 18 and 20 mm), and sterilized under UV light (30 min on each side). The 
280 agar petri dishes were inoculated with 200 µL of a suspension of S. aureus (107 Colony 
281 Forming Units per mL, CFU/mL). Samples were placed in the inoculated petri dishes (2 
282 samples/dish) with the side of thymol-loaded PLGA microparticles in contact with the agar 
283 in the case of PCL NFs@PLGA-THY MPs mats. 
284 2.6. In vitro cytotoxicity study
285 Human dermal fibroblasts (Lonza) and keratinocytes (HaCaT; kindly donated by Dr Pilar 
286 Martín-Duque) were used to evaluate the possible cytotoxic effects of the electrospun mats 
287 developed in a potential topical application.
288 Both cell lines were cultured at 37 °C in a 5 % CO2 atmosphere in DMEM containing L-
289 glutamine (2 mM) and supplemented with FBS (10 % v/v) and antibiotics (1 % penicillin-
290 streptomycin-amphotericin B). To assess the viability after treatment for 24h with free 
291 THY and with the electrospun materials developed, PCL NFs, PCL NFs@PLGA MPs and 
292 PCL NFs@PLGA-THY MPs, cells were seeded in 6-well plates (1.2 x 105 cells/well). 
293 After 24h to assure cell attachment, medium was discarded and replaced with fresh medium 
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294 and free THY or PCL NFs, or PCL NFs@PLGA MPs, or PCL NFs@PLGA-THY MPs 
295 mats were added. For the mats, 20 mm discs were cut and sterilized under UV light (1h for 
296 each side). For free THY, 0.52 mg/mL concentration was selected as represents the total 
297 amount of THY released in 24h from the 20 mm diameter PCL NFs@PLGA-THY MPs 
298 mats. After incubation for 24h, the Blue Cell viability assay (Abnova) was performed to 
299 study the viability related to cell metabolism. The mats were discarded, the medium 
300 replaced adding the reagent (10% v/v) and incubated for 4h (37 °C, 5 % CO2). Then, the 
301 fluorescence was read (535/590 nm ex/em) in a Synergy HT microplate reader (Biotek). 
302 Viability was calculated by data interpolation considering control samples (un-treated) as 
303 100 % viability. The data shown are obtained from six experiments run in duplicate (12 
304 data per material tested).
305 2.7. Preclinical wound infection model
306 The research was carried out under Project License 51/14 approved by the Ethic Committee 
307 for Animal Experiments of the University of Zaragoza (Spain). Eight to ten-week-old male 
308 SKH1 hairless mice (Charles River Laboratories) were used for this study. Mice were fed 
309 ad libitum and maintained under specific pathogen-free conditions accordingly with the 
310 Spanish Policy for Animal Protection RD53/2013, which meets the European Union 
311 Directive 2010/63 on the protection of animals destined to scientific purposes.
312 To evaluate wound infection and closure in murine skin avoiding wound contraction, the 
313 murine excisional wound splinting model with some modifications was carried out [24], as 
314 shown in Fig. 6A. This model mimics the human wound closure process through 
315 granulation and reepithelization by suturing a splinting ring around the wound, avoiding the 
316 typical murine healing through skin contraction [25]. Previously to the surgery and every 
15
317 day after surgery, mice were weighted to check the potential weight loss during the 
318 procedure. Animals were anesthetized with 5 % isoflurane, and maintained with 1-2 % 
319 isoflurane and an oxygen flow of 1 L/min. The skin surface was disinfected with 70 % 
320 ethanol (v/v). Meloxicam (2.5 mg/kg body weight) was then administered via sub-
321 cutaneous injection for pain relief before surgery and every day until 48h after surgery. 
322 Two 8-mm-diameter full-thickness wounds were made aseptically in the skin by using a 
323 sterile biopsy punch (Eickemeyer Veterinary Equipment Ltd.) in the thoracic region at each 
324 side of the median line. Then, two donut-shaped silicone wound splints (Grace Bio-Labs) 
325 were fixed into place around the wounds with six interrupted polyamide sutures (Dafilon 
326 4/0; Braun). After suturing, infected wounds were inoculated with S. aureus ATCC 25923 
327 (107 colony forming units (CFU) in 25 µL of PBS) and maintained uncovered for 15 min to 
328 allow the bacterial dispersion to penetrate in the wounded skin. It should be noted that a 
329 preliminary study of bacteria loading (102-109 CFU in 25 µL of PBS) was performed to 
330 determine the minimum bacteria concentration to achieve a durable infected wound 
331 considering the immunocompetence of the treated mice. After infection induction, different 
332 discs of 12-mm-diameter PCL NFs@PLGA MPs mats or PCL NFs@PLGA-THY MPs 
333 mats were piled up and placed onto the wounds to achieve the inhibitory THY 
334 concentration obtained in the in vitro assays described above. Then, in order to protect the 
335 wounds and the dressings, and to ensure an adequate progress of wound infection, an 
336 occlusive sterile adhesive plaster and a sterile bandage (Hartmann) were used to cover the 
337 wounds and splints. Mice were examined daily regarding infection progression, weight loss 
338 and pain.
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339 Twenty-four mice were experimentally divided in four groups (N = 6): i) Control group 
340 (wounds not infected); ii) Infected group (wounds infected and not treated with drug-
341 eluting dressings); iii) Infected group treated with PCL NFs@PLGA MPs mats; iv) Infected 
342 group treated with PCL NFs@PLGA-THY MPs mats. Each subgroup underwent the 
343 sacrifice of three mice at 3 days and 7 days after wound surgery and infection. At these 
344 time points, wound sizes were measured and photographed. All wounds were exposed from 
345 the third day after surgery and infection, as indicated in the clinical practice [26,27].
346 2.8. Microbiological evaluation of wounds
347 Infection levels of surgical wounds were quantified by using microbiological swabs with 
348 Amies media (Deltalab) after 3 and 7 days of the surgery and infection. Swabs were grown 
349 on blood agar and McConkey No. 3 media (Oxoid) and then incubated at 37 °C for 24h to 
350 semiquantify the S. aureus levels in the wounds. To carry out the identification of the 
351 microorganism, samples were reseeded and analyzed by a MALDI-TOF system (Bruker). 
352 Furthermore, at the same time points, swab samples were also analyzed by quantitative 
353 polymerase chain reaction (qPCR) to determine and quantify the presence of the 
354 experimental S. aureus ATCC 25923 strain in the wounds and the potential reduction of the 
355 bacteria levels in treated wounds. In brief, bacterial DNA was extracted from the samples 
356 with the DNeasy Blood & Tissue Kit (Qiagen) and then amplified by using the EXOone 
357 Staphylococcus aureus one MIX qPCR kit (Exopol) and a 7500 FAST Real Time PCR 
358 System (Applied Biosystems), following a pre-incubation step consisted in 1 cycle of 5 min 
359 at 95 °C whereas the amplification step comprised 42 cycles of 15 s at 95 °C and 1 min at 
360 60 °C. Then, the plate was read. All microbiological data were obtained from three 
361 independent experiments run in triplicate.
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362 2.9. Pathological studies
363 Animals were euthanized by CO2 inhalation at day 3 or day 7 after surgery and infection. 
364 Wound tissue samples were collected by carefully removing bandages, plasters, electrospun 
365 dressings, sutures and splints, along with 3 - 5 mm surrounding skin tissue. The wound 
366 samples were fixed in 4% buffered paraformaldehyde (Alfa Aesar) and embedded in 
367 paraffin. Five-micron-thick tissue sections were obtained and stained with hematoxylin and 
368 eosin (HE) staining for histopathological evaluation.
369 The pathological evaluation of the wounds also included measuring of angiogenesis by 
370 CD31 (Rabbit Polyclonal CD31 (ab28364), Abcam) using the automated immunostaining 
371 platform Autostainer Link (Dako). Briefly, slides were deparaffinized in xylene and re-
372 hydrated by means of an ethanol series until water. Prior to the primary antibody 
373 incubation, the antigen retrieval was developed by high pH buffer treatment (CC1m, 
374 Roche) and the endogenous peroxidase was blocked through addition of 3% H2O2. Slides 
375 were then incubated with the primary antibody (Rabbit Polyclonal CD31 1:50 for 60 min) 
376 to be followed by the corresponding visualization system conjugated with horseradish 
377 peroxidase (EnVision FLEX+, Dako). The immunohistochemical reaction was carried out 
378 with the chromogen 3, 30-diaminobenzidine tetrahydrochloride (DAB), whereas Carazzi's 
379 hematoxylin was used for nuclei staining. For microscopic evaluation, the slides were then 
380 dehydrated and permanent mounted.
381 2.10. Statistical analysis
382 All statistics were performed using GraphPad software. Data are reported as mean ± SD. To 
383 test for statistical significance, two-way analysis of variance (ANOVA) for multiple 
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384 comparisons by Dunnett’s multiple comparisons test was employed. Significant differences 
385 were considered when p ≤ 0.05.
386 3. Results
387 3.1. Characterization of asymmetric electrospun antimicrobial dressings
388 In order to obtain reproducible drug-release kinetics, microparticle homogeneity in the 
389 electrosprayed materials was sought. Therefore, different THY concentrations and different 
390 flow rates used in the PLGA electrospraying were evaluated (Fig. 1). Particle size 
391 distributions revealed 1 mL/h flow rate and 10 wt.% THY concentration as the 
392 experimental conditions that produced a homogeneous particle size distribution (0.728 ± 
393 0.143 µm) on the electrospun mats. At the same flow rate (0.5 mL/h), increasing the THY 
394 concentration (5 - 15 wt. %) a narrower particle-size distribution was found at 10 wt. % 
395 (Fig. 1C). At the same THY concentration (10 wt. %), a narrower particle size distribution 
396 was obtained with the highest flow rate tested (1 mL/h). Those conditions (10 wt.% THY 
397 and 1 mL/h flow rate) were selected for the subsequent experiments.
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417
418 Fig. 1. Synthesis optimization for THY-loaded PLGA microparticles. A) 5 % THY, 0.5 
419 mL/h; B) 7.5 % THY, 0.5 mL/h; C) 10 % THY, 0.5 mL/h; D) 15 % THY, 0.5 mL/h; E) 10 
420 % THY, 1.0 mL/h; F) histogram of microparticles from image E (N = 100).
421 Figure 2 shows the increase in the microparticle loading on the electrospun NFs over time. 
422 The longer the electrospraying time, the higher the microparticle loading. Also PLGA MPs 
423 preferentially attached to the NFs and no loosely bound microparticles were found. The 
424 large area per volume ratio of the electrospun PCL mat provided with large surface area 
20
425 available for electrostatic interaction. Microparticles were not present on the other side of 
426 the mat, therefore they did not percolate throughout the electrospun mat (Fig. 2F).
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439
440 Fig. 2. Microparticle attachment on the electrospun PCL nanofibers over time: A-D) 
441 nanofibers surface after 0.5, 1, 1.5 and 2h of microparticle electrospraying, respectively; E) 
442 top-side view of electrospun PCL nanofibers after 2h of microparticle electrospraying; F) 
443 bottom-side of the mat after 2h of microparticle electrospraying. N = 100.
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444 To test the strong attachment between the PLGA MPs and the electrospun NFs, mechanical 
445 stress was evaluated by means of ultrasonic energy. The resulting mats were immersed in 
446 water and subjected to 40 kHz at a constant power of 360 W up to 18 min at room 
447 temperature. As is shown in Fig. 3 (A-D), the cavitation bubbles induced by the high 
448 frequency sound waves did not detach the MPs from the electrospun PCL NFs. No PLGA 
449 MPs were found on the bottom side of the mat indicating that the MPs were not able to 
450 cross the 36 ± 8 µm-thick (evaluated by an analogic micrometer) mats due to their inherent 
451 tortuosity. We assume that PLGA MPs could not percolate through the mats but as 
452 observed the mats preserved porosity to allow vapor exchange.
453 The tensile strength (2.8 ± 0.2 MPa) and strain at break (174.0 ± 12.4%) values obtained for 
454 the unloaded mats are in agreement with the previously reported values for PCL fibers 
455 decorated with PLGA particles [28]. The incorporation of THY in the MPs slightly changed 
456 these values, so the tensile strength measured was 2.7 ± 0.8 MPa whereas the strain at break 
457 was 168.4 ± 0.4%. This fact was expected since the mechanical properties of the mats are 
458 mainly given by PCL fibers that are not modified by THY incorporation. The tensile 
459 strength was in the required range for wound dressing applications while the mats 
460 elongation-at-break was around 140% higher than the value of the human skin [29].
461 The amount of PLGA and THY in the final mats was evaluated by means of NMR. As it is 
462 shown in Fig. 3E, a PLGA content of 11.28 ± 3.39 and 17.46 ± 2.15 wt. % were obtained 
463 for the PCL electrospun NFs decorated with PLGA microparticles (PCL NFs@PLGA 
464 MPs), and for the PCL electrospun NFs decorated with electrosprayed thymol-loaded 
465 PLGA microparticles (PCL NFs@PLGA-THY MPs), respectively. The amount of THY 
466 present in the mats was also evaluated by GC-MS and similar results were obtained from 
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467 both techniques (Fig. 3E). Therefore, THY is present in the mats and is available to be 
468 released upon contact with any aqueous solution due to the hydrolytic character of its 
469 carrier (i.e., PLGA). The PLGA used has a 50:50 lactic:glycolic ratio so a sustained release 
470 over its degradation life span (< 3 months) would be expected. Drug release kinetics were 
471 evaluated in PBS with Tween 80 (2 % w/v) at 37 °C with a constant agitation (250 rpm) 
472 under sink conditions (Fig. 3F). The UPLC analysis revealed an initial burst with a 60.12 ± 
473 7.71 wt.% of THY released in the first 3h, to be then sustained until 24h when the 
474 cumulative release measured was around 70 %. 
475 In order to analyse the release behaviour of THY from the PLGA particles the first 60 % of 
476 the experimental release data were fitted with several mathematical models (data not 
477 shown). The Peppas-Sahlin model with a coefficient of lineal correlation (R2) of 0.995 was 
478 chosen as the appropriate model for explaining the release kinetics [30]. The coefficient n is 
479 the purely Fickian diffusion exponent, the value of 0.69 would indicate an anomalous 
480 transport mechanism. In this kind of release mechanism, Fickian diffusion through the outer 
481 layers of the matrix and polymer chain relaxation/erosion are both involved. The constant 
482 k1 (48.77 h-n) is associated with the diffusional release while k2 (-9.71 h-2n) is related to 
483 relaxation processes. Even when the contribution of both mechanisms is considered to be 
484 additive, as the k1/ k2 ratio is around 5, the contribution of the Fickian diffusion would 
485 control the release process. 
486
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503 Fig. 3. Characterization of PCL NFs@PLGA-THY MPs mats: A-D) Evaluation of the 
504 attachment between the PLGA MPs and the electrospun PCL NFs by mechanical stress 
505 after 0, 6, 12 and 18 min under sonication in water, respectively; E) PLGA and THY 
506 loading in NFs evaluated by GC-MS and 1H-NMR (Mean ± SD of three different samples 
507 analyzed in duplicate); F) Release profile of THY from PCL NFs@PLGA-THY MPs. 
508 Mean ± SD; 18 data per time point.
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509 3.2. Antimicrobial and cytocompatibility of dressings 
510 The antibacterial effect of the materials developed (PCL NFs, PCL NFs@PLGA MPs and 
511 PCL NFs@PLGA-THY MPs) against S. aureus was corroborated by the measurement of 
512 the inhibition zone displayed by the drug loaded electrospun disc placed on the agar as an 
513 indication of the absence of viable bacteria (Fig. 4E and F). Discs of different diameters 
514 (12, 14, 18 and 20 mm) were assayed though no antibacterial effect was found in diameters 
515 lower than 20 mm. Therefore, we set 20 mm (28.9 ± 4.6 mg) as the minimum required 
516 diameter to elicit antibacterial action considering the amount of THY loaded in the MPs 
517 attached to the electrospun mats and the bacterial burden (107 CFU/mL). Fig. 4 shows that, 
518 at the two time points measured (after 1 and 5 days), no inhibition zone was observed for 
519 the PCL NFs (Fig. 4A and B) or for the PCL NFs@PLGA MPs (Fig. 4C and D), but an 
520 inhibition zone around the discs was observed for the PCL NFs@PLGA-THY MPs (Fig. 
521 4E and F), indicative of the presence of an antimicrobial compound in the medium. The 
522 diameter of the inhibition zone increased over time (24.8 ± 0.2 mm at day 1; 29.9 ± 0.6 mm 
523 after 5 days), which was indicative of a sustained release of the antimicrobial compound 
524 through the agar and that the strain used was susceptible to THY.
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538
539 Fig. 4. Representative images of antimicrobial disk diffusion test after 1 day (A, C, E) and 
540 5 days (B, D, F) of treatment with the different mats developed: A, B) PCL NFs; C, D) 
541 PCL NFs@PLGA MPs; E, F) PCL NFs@PLGA-THY MPs. Scale bar = 10 mm.
542
543 On the other hand, the cytocompatibility of the synthesized mats (PCL NFs, PCL 
544 NFs@PLGA MPs and PCL NFs@PLGA-THY MPs) and the corresponding free THY 
545 released in 24h (0.52 mg/mL) from the PCL NFs@PLGA-THY MPs mats (20 mm 
546 diameter) was also evaluated against human dermal fibroblasts and keratinocytes after 24h 
547 treatment. As can be seen in Fig. 5, no cytotoxicity was observed for the 20 mm mats in the 
548 time studied displaying percentages of viability above 80%. Controversially, the total 
549 amount of THY released after 24h in the mats exerted a strong cell damage with viabilities 
550 as low as 8-10% compared to the un-treated controls. According to the ISO 10993-5 
551 standard [31], a viability above 70% is considered as the threshold for considering a 
26
552 compound as non-cytotoxic and therefore, the drug loaded mats were not cytotoxic for 
553 those two cell lines studied, whereas the free monoterpenoid strongly reduced cell viability. 
554 According to the in vitro THY-release test (Fig. 3F) at 24h the dressings released a 71.07 ± 
555 8.11 % of the THY loaded; hence the non-cytotoxic character of the asymmetric 
556 electrospun mats may be attributed to the sustained release of THY.
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564 Fig. 5. In vitro cytotoxicity results obtained from human dermal fibroblasts and 
565 keratinocytes (HaCaT) treated for 24h with the synthesized mats (PCL NFs, PCL 
566 NFs@PLGA MPs and PCL NFs@PLGA-THY MPs) and free THY released in 24h (0.52 
567 mg/mL) from the PCL NFs@PLGA-THY MPs mats. Mean values and SD obtained from 
568 six different experiments in duplicate (N = 12).
569 3.3. In vivo evaluation of the antimicrobial action of the dressings in an infection 
570 wound excisional murine model 
571 To investigate the in vivo efficacy of the fabricated mats, 12-mm-diameter PCL 
572 NFs@PLGA MPs and PCL NFs@PLGA-THY MPs were evaluated in a murine excisional 
27
573 wound splinting model [24], as depicted in Fig. 6A. Even though 12-mm-diameter PCL 
574 NFs@PLGA-THY MPs mats were not found to exert antibacterial effect in the inhibition 
575 zone assay, as described above, different discs of this diameter were piled up to obtain the 
576 same mats weight (28.9 ± 4.6 mg) in order to fully cover the surgical wound, achieving the 
577 same THY released as in the 20-mm-diameter disc. The use of discs of larger diameter than 
578 12 mm was not advisable due to the wound’s diameter selected in the experimental model.
579 Mice wound contraction was inhibited by suturing a splinting ring around the edge of the 
580 wound to mimic the human wound healing process [24]. After S. aureus infection, PCL 
581 NFs@PLGA MPs and PCL NFs@PLGA-THY MPs were held in place with occlusive 
582 sterile round spot adhesive plasters and sterile bandages. The control group was not treated 
583 with the fabricated mats but covered with plaster and bandages. On day 3 after surgery and 
584 infection, wounds were uncovered as recommended in the clinical practice [26,27]. Figure 
585 6B shows that after a week, the PCL NFs@PLGA MPs and the PCL NFs@PLGA-THY 
586 MPs mats slightly reduced the bacterial load from a massive uncountable load (+++) to 
587 high bacterial counts (++). Non-treated but infected animals showed massive uncountable 
588 loads by the end of the experiment whereas not infected wounds remained uninfected until 
589 the end of the experiments (data not shown). Furthermore, microbiological qPCR (Fig. 6C) 
590 corroborated the previous findings having a significant reduction in the infective strain at 7 
591 days post infection. 16S rRNA PCR was used to identify the specific strain S. aureus 
592 ATCC 25923 with a statistically significant reduction in the bacterial load quantified after 7 
593 days of surgery and infection.
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606 Fig. 6. In vivo infection wound excisional model in SKH1 mice and treatment with the 
607 synthesized materials: A) Schematic overview of the in vivo procedure; B) Representative 
608 images of wound evolution at 3 and 7 days after surgery and infection (INF). Insets show 
609 the microbiological results regarding bacteria colony counting ((++) high number of 
610 colonies; (+++) massive culture); C) Microbiological qPCR results. Data are expressed as 
611 Mean ± SD of three separate experiments run in triplicate. Significant differences were 
612 found between INF group vs treated groups after 7 days (*p ≤ 0.05).
613
614 Histopathologic studies were performed to analyze infection progress, wound repair and 
615 angiogenesis in infected and non-infected mat-treated groups (Fig. 7 and 8). Intensity of 
29
616 lesions was similar in all cases between 3- and 7-days post-infection (dpi), including severe 
617 inflammation in subcutaneous tissue that reached the adipose and muscular layers of the 
618 dermis. At 7 dpi there was always a higher degree of tissue fibroplasia and repair (Fig. 7). 
619 New blood vessel formation was studied by immunostaining against CD31 and using a 
620 semi quantitative approach. Blood vessels were more abundant in the vicinity of the wound 
621 in the PCL NFs@PLGA-THY MPs treated group (Fig. 8).
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635 Fig. 7. Histopathological assessment of wound infection and treatment by hematoxylin-
636 eosin staining (10x). Representative images of the control group (A, B), infection group (C, 
637 D), PCL NFs@PLGA MPs treated group (E, F) and PCL NFs@PLGA-THY MPs treated 
638 group (G, H), at 3 (A, C, E, G) and 7 (B, D, F, H) days after surgery and infection, are 
639 shown. Control animals show either no reaction around the limit of the wound (A) or 
640 formation of granulation tissue, which is characteristic of sterile wound repair (B). The 
641 infection group or both treated groups show a similar severity degree of inflammatory 
642 reaction between 3 and 7 days, compared to the controls. A higher degree of fibroplasia and 
643 repair is generally observed at 7 dpi (arrows).
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655 Fig. 8. Immunohistochemical staining of CD31 of the subcutaneous tissue surrounding the 
656 wound in infected and treated tissue samples at 3 dpi (20x). (A) Representative image of 
657 the infection group. Minimal presence of blood vessels (brown staining, arrows). (B) PCL 
658 NFs@PLGA-THY MPs treated group. Multiple, abundant blood vessels (brown staining, 
659 arrows). 
660 4. Discussion
661 During the electrospraying process, the organic solvent present in the droplets leaving the 
662 Taylor cone rapidly evaporates, with the consequent flash polymer precipitation producing 
663 a reduced drug loss in its flight towards the counter electrode. Based on our previous 
664 experience, we decided to keep several synthesis parameters constant (needle gauge, 
665 distance to collector, solvent, temperature and humidity) and vary only two (THY 
666 concentration and flow rate). Regarding THY concentration, different THY wt.% (2.5 - 15) 
667 referred to the PLGA mass used were employed. The increase in THY concentration at the 
668 same flow rate (0.5 mL/h) did not involve significant changes in MPs sizes (Fig. 1) nor 
669 even a clear trend, as previous studies concerning PLGA MPs electrosprayed on polymeric 
670 mats have shown [32]. However, the highest THY concentration assayed (15 %) entailed an 
671 increase in MPs size up to 2.847 ± 0.706 µm though showing heterogeneous particle-size 
672 distributions. The increase in flow rate up to 1 mL/h and 10 wt.% THY concentration were 
673 found as the most appropriate conditions to obtain a homogeneous particle-size distribution 
674 (0.728 ± 0.143 µm). Interestingly, THY loaded particles did have larger size when 
675 entrapped in the fabricated mats (Fig. 2) (1.634 ± 0.277 µm). These results are in 
676 accordance with previous works that highlighted the relevance of polymeric chain 
677 entanglements in electrospraying techniques, becoming decisive in the size and 
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678 morphology of the synthesized MPs and allowing to customize the most adequate release 
679 kinetics for drug delivery purposes [32–34]. The preferential and strong attachment of 
680 PLGA MPs to PCL NFs was also demonstrated (Fig. 2 and 3), which may be related to 
681 supramolecular interactions based on the large area per volume ratio exhibited by the 
682 electrospun PCL NFs.
683 On the other hand, THY release kinetics were fitted into different models, being the Peppas 
684 and Sahlin model the most suitable to explain the THY release of around 60 % in the first 
685 3h followed by a period of sustained release  until 24h, reaching 70 % cumulative release 
686 (Fig. 3F). This release trend is consistent with the medium in which it was performed (PBS) 
687 and the efficient entrapment of THY in PLGA after the first hours, as previously reported 
688 [35,36]. As mentioned above, the sustained and prolonged release of antimicrobials from 
689 dressings are highly desired as infections may take place during wound healing. In addition, 
690 the use of natural substances as antimicrobial active compounds has attracted attention in 
691 the last years owing to the multiple mechanisms of antimicrobial action compared to 
692 antibiotics. In this regard, THY recommended daily dermal administration according to the 
693 European Chemicals Agency (ECHA) is below 2000 mg/kg bw [37]. Subsequently, THY 
694 release reported from our PCL NFs@PLGA-THY MPs mats is expected to be safe for 
695 wound healing applications.
696 Asymmetric electrospun PCL-silk fibroin and hyaluronan-silk fibroin membranes loading 
697 THY also displayed a kinetic release of THY similar to our results, showing an initial burst 
698 in the first 8h followed by a sustained release up to 24h. This trend may be connected to the 
699 high surface to volume ratio of the NFs that favors the diffusion of THY from the 
700 membranes to the release media [38].
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701 THY biological effects are diverse, from anti-inflammatory to antibacterial. It may exert 
702 these effects at low concentrations, being different depending on the delivery system from 
703 which THY is released and on the microorganism strain challenged [35,39]. Our fabricated 
704 PCL NFs@PLGA-THY MPs mats (20 mm diameter) clearly displayed an inhibition zone 
705 in S. aureus inoculated agar Petri dishes (Fig. 4E and F) which increased over time (~ 5 
706 mm at day 1, ~ 10 mm at day 5), pointing to an in vitro sustained release of THY. Other 
707 drug delivery systems loaded with THY have also shown the successfully inhibition of 
708 bacterial growth, such as THY enriched bacterial cellulose hydrogel (1% THY) [40], 
709 ethylcellulose/methylcellulose sub-micron spheres [39] or our previous studies regarding 
710 PCL NFs [22]. Gelatin films incorporated THY at different concentrations (1 - 8 %) also 
711 displayed antibacterial effects against S. aureus showing larger inhibition zones with the 
712 increase in concentration (1 - 15 mm in 24h) [41]. According to 195920-ASTM E2149-01 
713 norm, an inhibition zone higher than 1 mm is considered as a good antibacterial agent [41]. 
714 Hence, it may be concluded that the synthesized PCL NFs@PLGA-THY MPs dressings 
715 exhibited excellent in vitro antibacterial properties against S. aureus and thus, their 
716 potential application in the clinical practice as regards infected wound treatment and 
717 healing is granted.
718 In this sense, the evaluation of the in vitro cytocompatibility of these mats in human dermal 
719 fibroblasts and keratinocytes cultures also highlighted their suitability as compatible mats 
720 (> 80 %) whereas free THY at the concentration released in 24h (0.52 mg/mL) dramatically 
721 diminished viability (8 - 10 %). This trend was also observed in previous cell viability 
722 studies involving THY loaded bacterial cellulose hydrogels in NIH 3T3 murine fibroblasts 
723 up to 72h [40] or THY loaded asymmetric electrospun PCL-silk fibroin/hyaluronan-silk 
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724 fibroin membranes in human dermal fibroblasts up to 7 days [38]. Overall, the obtained 
725 results confirm the potential of the fabricated electrospun PCL NFs@PLGA-THY MPs 
726 mats as wound dressings.
727 To test the in vivo application of the synthesized mats, we investigated their effects in an 
728 infected murine excisional wound splinting model (Fig. 6 - 8). Surgical wounds were 
729 infected with S. aureus ATCC 25923 and not treated (infection control group), or treated 
730 with PCL NFs@PLGA MPs or PCL NFs@PLGA-THY MPs mats. The microbiological 
731 studies (Fig. 6B and C) demonstrated the in vivo inhibitory potential of S. aureus infection 
732 showing the significant reduction of the infective strain load in treated wounds, though the 
733 total eradication of infection after treatment was not achieved due to the high bacterial load 
734 experimentally introduced (4.108 CFU/mL). Furthermore, only slight differences were 
735 found in wounds treated with PCL NFs@PLGA MPs or PCL NFs@PLGA-THY MPs after 
736 7 days (107 copies/mL and 106 copies/mL, respectively). This may be related to the 
737 incomplete contact of the whole dressing with the infected wound to successfully achieve 
738 the direct exposure of bacteria with the antibacterial compound, as we previously described 
739 [22] and to the in vivo diffusion and washing of the antimicrobial compound. It should be 
740 noted that different discs of the mats of 12 mm of diameter were piled up to cover the 
741 infected wounds in order to obtain the same mats mass and amounts of THY released as the 
742 one displayed by the membranes used in the in vitro assays regarding the inhibition of 
743 bacteria growth. Thus, only the disc in direct contact with the wound may exert the 
744 antimicrobial action but not those which were above, hampering the potential inhibitory 
745 effects of released THY on bacterial growth. Moreover, previous studies have highlighted 
746 that the amount of drug or natural compound released from loaded scaffolds in PBS may 
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747 not be the same as that released on an agar plate arising from the differences in drug or 
748 natural compound solubility and/or solution volume, though the relative trends may be 
749 similar since PBS and agar has the same pH [36]. Taking this observation into account, the 
750 environment present in a wound may play a key role in drug or natural compound released 
751 and thus, in its biological effects, regarding the presence of different substances (i.e. 
752 cytokines, vitamins, hormones, enzymes) whose levels dynamically change in the different 
753 stages of healing [42]. Therefore, it is expected that the release trend of a compound may 
754 differ in in vitro and in vivo conditions as we describe, being not feasible to exactly mimic 
755 in vitro the in vivo microenvironment of an infected wound due to its complexity and 
756 multistage dynamic nature.
757 5. Conclusions
758 This study presents the development of electrospun PCL-based mats incorporating PLGA 
759 MPs loading THY as antibacterial compound. Dressings with a THY load higher than 1.2 
760 % w/w were achieved. The fabricated mats were able to successfully inhibit S. aureus in 
761 vitro growth when containing THY. Their cytocompatibility was also demonstrated 
762 showing viabilities higher than 80 % in human dermal fibroblasts and keratinocytes 
763 cultures after 24h treatment, whereas free THY at the same concentration released after 24h 
764 was significantly detrimental for eukaryotic cells. In vivo studies involved the development 
765 of the murine excisional wound splinting model followed by the infection of wounds with a 
766 high load of S. aureus and their treatment with the synthesized dressings. The 
767 microbiological and histopathological evaluation of the wounds after 3 and 7 days of 
768 surgery and infection revealed the inhibition of the bacteria load in wounds after 7 days 
769 though the complete eradication of the infection was not obtained. Moreover, PCL 
36
770 NFs@PLGA MPs and PCL NFs@PLGA-THY MPs dressings displayed similar results, 
771 which may be related with the circumscribed inhibitory effect of the THY loaded dressings 
772 to the contact area with the wound, as we previously described, and the differences in THY 
773 release in vitro and in vivo. This work validates in vivo our previous observations regarding 
774 the importance of the close contact between the antibacterial dressing and pathogenic 
775 bacteria, highlighting the need to customize or adapt the dressing considering the wound 
776 surface and the antimicrobial compound loading.
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